Anergis Closes CHF 18 Million Series A Financing Round to develop its Innovative Allergy Vaccines and Expands its Board of Directors

29-Mar-2011 - Switzerland

Anergis SA announced that it has closed a Series A financing round raising CHF 18 millions from European biotech funds and private local investors.

Anergis SA is a clinical-stage biopharmaceutical company developing innovative immunotherapies against allergies. Its lead product, called “AllerT” and made of so-called Contiguous Overlapping Peptides (COPs), is designed to provide ultra-fast and safe desensitization to birch pollen allergy, a widely spread condition in developed countries.

The financing round was co-led by three major European funds with extensive biotech experience: Vinci Capital-Renaissance PME (Lausanne, Switzerland), BioMedInvest (managed by BioMedPartners AG, Basel, Switzerland) and Sunstone Capital (Copenhagen, Denmark). The syndicate was also joined by Esperante (Limhamn, Sweden), Initiative Capital Romandie (Lausanne, Switzerland) and by private investors. Up until now, Anergis has invested CHF 3 million in its innovative allergy vaccines. These funds were raised from private investors and from a grant by the Swiss Innovation Fund (CTI).

The newly joining investors also bring substantial pharmaceutical experience and know-how to Anergis: Patrick Scherrer (representing Vinci Capital-Renaissance PME), Markus Hosang (representing BioMedInvest) and Sten Verland (representing Sunstone Capital) have joined the Anergis Board of Directors.

The Board will be chaired by André J. Mueller, a professional with unique executive and non-executive experience in biotech ventures, which he gained with Biogen and Actelion and as the Chairman of the Boards of Cerenis Therapeutics (Toulouse) and Addex Pharmaceuticals (Geneva).

“The proceeds of this financing will cover our financial requirements for the next two years and will allow us to take essential steps for the development of Anergis. In particular, we will now conduct a large Phase II multicenter trial with AllerT, our lead product for patients allergic to birch pollen, and we will speed up the preclinical development of our product portfolio in our new research laboratories,” said Vincent Charlon, PhD, CEO of Anergis.

https://www.bionity.com/en/news/131611/anergis-closes-chf-18-million-series-a-financing-round-to-develop-its-innovative-allergy-vaccines-and-expands-its-board-of-directors.html